In addition, several studies have confirmed that CYP1A2 also possesses a certain metabolic capacity for AAI; by inducing the expression of CYP1A2, the formation of carcinogenic AAI–DNA adducts can be inhibited, thereby reducing the risk of cancer development [52]. The gene discussed is CYP1A2; the disease is cancer.